Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing HMGB1 and inflammatory cytokines

In conclusion, rTM suppressed inflammatory mediators in the peripheral circulation and prevented HMGB1 release from nuclei in the central nervous system, suppressing EAE‐related inflammation. rTM could have a novel therapeutic potential for patients with multiple sclerosis. This article is protected by copyright. All rights reserved.

Source: Clinical and Experimental Immunology - March 1, 2018 Category: Allergy & Immunology Authors: Akiyuki Uzawa, Masahiro Mori, Hiroki Masuda, Ryohei Ohtani, Tomohiko Uchida, Satoshi Kuwabara Tags: Original Article Source Type: research